BMX-502

N/A

Report date: 2026/03/23 20:03:44

First In Class

Base Information

Drug NameBMX-502

Drug Alias NameBMX-502

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Glypican-3

TargetsGlypican-3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBiomunex Pharmaceuticals SAS

China Registration ClassN/A

Develop Information

Active CompaniesIpsen Biomunex Pharmaceuticals SAS

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A